You have been chosen to receive this valuable information.

The manufacturing of a biotherapy involves multiple inputs, ranging in complexity from a transfection reagent to the host cell in which the therapy is manufactured. All of these process components should be removed prior to the therapy being available for human use.

During this webinar we will review strategies within product characterization to de-risk the manufacturing process for cell and gene therapies and monoclonal antibodies (mAbs).

We will focus on how we effectively detect and characterize:

•	polyethylenimine (PEI), used in cell and gene therapy products; and
•	host cell proteins, a factor in mAb therapies and cell and gene therapies.

Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of BioPharm International, a UBM publication. You are on the mailing list as %%emailaddress%%.